These findings provide new insights into the complex regulatory networks governing HCC progression and highlight the potential of targeting IFI16 and its interactions with other proteins, such as p53 and DLK1, for therapeutic intervention in this disease. This evidence concerns the gene IFI16 and hepatocellular carcinoma.